Search results
Results from the WOW.Com Content Network
If the thrombosis developed under temporary circumstances (e.g. pregnancy), three months are regarded as sufficient. If the condition was unprovoked but there are no clear causes or a "mild" form of thrombophilia, 6 to 12 months is advised. If there is a severe underlying thrombosis disorder, warfarin treatment may need to continue indefinitely ...
Cerebral atherosclerosis is a type of atherosclerosis where build-up of plaque in the blood vessels of the brain occurs. Some of the main components of the plaques are connective tissue, extracellular matrix, including collagen, proteoglycans, fibronectin, and elastic fibers; crystalline cholesterol, cholesteryl esters, and phospholipids; cells such as monocyte derived macrophages, T ...
On CT scans, brain parenchymal hemorrhage that does not confined to specific arterial territory along with hyperdense appearance on dural venous sinuses raises the suspicion of DVST. Further evaluation with CT venography, MR venography, and post gadolinium MRI provides accurate diagnosis of venous thrombosis and follow-up after treatment.
Yellow softening is the third type of cerebral softening. As its name implies, the affected softened areas of the brain have a yellow appearance. This yellow appearance is due to atherosclerotic plaque build-up in interior brain arteries coupled with yellow lymph around the choroid plexus, which occurs in specific instances of brain trauma. [2]
Brain ischemia is insufficient blood flow to the brain, and can be acute or chronic. Acute ischemic stroke is a neurological emergency typically caused by a blood clot blocking blood flow in a vessel in the brain. [15] Chronic ischemia of the brain may result in a form of dementia called vascular dementia. [16]
Thrombosis prevention or thromboprophylaxis is medical treatment to prevent the development of thrombosis (blood clots inside blood vessels) in those considered at risk for developing thrombosis. [1] Some people are at a higher risk for the formation of blood clots than others, such as those with cancer undergoing a surgical procedure.
The management of ATE depends on the location and severity of the ischemia and the underlying etiology. The main goals of ATE management are to restore blood flow, prevent further thrombosis, and treat the underlying cause. The treatment options for ATE include antithrombotic therapy, revascularization procedures, and risk factor modification.
Treatment for thrombotic storm may include lifelong anticoagulation therapy and/or thrombolytic therapy, plasmapheresis, and corticosteroids. Studies have shown that when anticoagulant therapy is withheld, recurrence of thrombosis usually follows. International normalized ratio is closely monitored in the course of treatment.